摘要 |
PROBLEM TO BE SOLVED: To provide a beneficial medicine of compounds having biological activity equal to that of natural lipoxins, but a longer in vivo half-life, though the lipoxins are small molecules administerable in vivo to a plurality of diseases and conditions, but they have a short life in vivo. SOLUTION: Lipoxin analogs having an active region that is the same or similar to that of natural lipoxin, but a metabolic transformation region which is more resistant to in vivo catabolism, are provided. Therefore, the lipoxin analogues have the biological activity of natural lipoxins, but a longer metabolic half-time. Some of the lipoxin analogs may additionally have an increased in vivo potency, higher binding affinity to lipoxin receptors or enhanced bioactivity in comparison with natural lipoxins. COPYRIGHT: (C)2011,JPO&INPIT
|